BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Vesalius, Rondo Debut to Redefine Treatment Paradigms

  Flagship will pour in $75 million into Vesalius to support its beginnings, while Rondo raised $67 million to support the development of its preclinical pipeline.

  March 2, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Adagene and Sanofi Tie Up in $2.5B Antibody Collab

  Shares of Adagene Inc. are up more than 10% in premarket trading after the company announced a monoclonal and bispecific antibody collaboration with Sanofi valued at up to $2.5 billion.

  March 2, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  SEC Wades into Confusion Over FibroGen Safety Data in Anemia Drug

  FibroGen is tangled up in a Securities Class Action Litigation and Derivative Litigation concerning clinical trial data for its drug Roxadustat.

  March 2, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  Pfizer’s RSV Vaccine Reaches “Pivotal Next Step” with Breakthrough Therapy Designation

  Pfizer announced its RSV vaccine candidate PF-06482077 or RSVpreF, received Breakthrough Therapy designation from the U.S. Food and Drug Administration.

  March 2, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Global Roundup: PneumoWave’s Opioid Overdose Device, Sputnik V and German Innovation

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

  March 2, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  FDA

  FDA Formalizes Celyad CAR-T Trial Hold while Risks Evaluated

  Belgium-based Celyad Oncology voluntarily paused a clinical trial with Merck after two deaths. Getting CAR T therapies to work in solid tumors has proven to be a difficult challenge.

  March 2, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Clinical Trials Paused in Russia as Conflict Hits Day 7

  First Moscow State Medical University has paused recruiting new patients for its ongoing clinical trials following a disruption in the university’s ability to receive clinical trial samples.

  March 2, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  LEXEO Gene Therapy for Alzheimer’s Shows Early Promise

  LEXEO Therapeutics has announced positive initial data from its Phase I/II trial of LX1001, a gene therapy intended for the treatment of APOE4 homozygous Alzheimer’s disease (AD).

  March 2, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Elgan’s Infant Malabsorption Treatment Reduces Complications in Phase III

  The Phase III study showed that ELGN-GI not only improved gastrointestinal (GI) function, but it also reduced life-threatening complications.

  March 2, 2022

   · 

  3 min read

   · 

  Claudia Beezhold
• 

  Policy

  Lessons from Past Wars Could Offer Insight for Biopharma During Ukraine War

  Throughout history, many different countries have had their biopharma supply chains changed – sometimes profitably, sometimes detrimentally – by war.

  March 2, 2022

   · 

  6 min read

   · 

  Hannah Chudleigh